Biogen has appointed Daniel Quirk as its new chief medical officer and Robin Kramer as chief financial officer, succeeding Michael McDonnell, who will retire in February. Meanwhile, Novartis has written down $800 million in goodwill related to its MorphoSys acquisition, delaying the approval of the drug pelabresib for myelofibrosis. Additionally, Sanofi has invested in Resalis Therapeutics, which is developing an RNA medicine for metabolic diseases, while Moderna and Merck & Co. have launched a third Phase 3 trial for their personalized cancer vaccine in lung cancer.
Biogen has appointed Daniel Quirk as Medical Director and Head of Medical Affairs, effective October 28, 2024. Quirk, who previously served as senior vice president of global medical affairs for immunology and neuroscience at Bristol-Myers Squibb, will report to Priya Singhal, Head of Development.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.
